Oligonucleotide manufacturer Girindus has named Edward Huber as its director of analytical development and quality control.
Huber previously held a variety of positions at Marion Merrell Dow, Hoechst Marion Roussel, Aventis, and Patheon. He has a PhD in analytical chemistry from the University of Cincinnati.
Agios Pharmaceuticals has appointed Alnylam Pharmaceuticals CEO John Maraganore to its board of directors.
Maraganore is the first independent director of Agios, which is developing drugs in the area of cancer metabolism.
Prior to Alnylam, Maraganore was an officer and a member of the management team for Millennium Pharmaceuticals, where he was oversaw the company's efforts in oncology, cardiovascular, inflammation, and metabolic diseases. Before Millennium, he worked in molecular biology and business development at Biogen, ZymoGenetics, and the Upjohn Company.